Danger From Heart Surgery Drug Confirmed

FDA says manufacturer of Trasylol now removing remaining stock of drug from U.S. market, following new data on increased death risk.

By Steven Reinberg
HealthDay Reporter

Related Encyclopedia • Alzheimer's Disease • Aneurysms • Angina Pectoris • Angiogram More... Related Healthscout Videos The On-X Valve PROACT Trial The On-X Heart Valve: Longevity With Less Reliance on Coumadin Tissue Valves vs. Mechanical Valves What is the difference between heart valve repair and replacement? More... Related Animations • Alzheimer's Disease Video Animation • Angioplasty • Coronary Bypass Surgery • Erectile Dysfunction More... Related Drug Information • Accupril • Actonel • Altace • Avapro More... Related News Articles • Work Strife Stresses the Heart • Abnormal Heartbeat After Bypass a Bad Sign • Lowered HRT Use May Have Cut Heart Attacks • With Peripheral Artery Disease, Med Adherence Is Low More...

WEDNESDAY, May 14 (HealthDay News) -- A new Canadian study confirms that people given Trasylol, a drug used to reduce bleeding during heart surgery, face a 53 percent increased risk of death.

Trasylol's German maker, Bayer AG, suspended marketing in the United States last November after preliminary results from this trial revealed problems with the medication. On Wednesday, following release of the new findings, the U.S. Food and Drug Administration said the manufacturer had begun removing any remaining stock of the drug from the U.S. market.

Text Continues Below

---

"In the trial, we asked whether aprotinin [Trasylol] was more effective at reducing massive bleeding during high-risk heart surgery compared to other drugs," lead investigator Dr. Dean A. Fergusson, from the University of Ottawa Centre for Transfusion Research, said during a teleconference Monday.

"We also asked were serious complications, such as death and organ failure, lower for aprotinin compared to the two other drugs," Fergusson said.

The report was released online Wednesday by the New England Journal of Medicine and will appear in its May 29 issue.

In the Canadian trial, known as BART, Trasylol was compared with two similar drugs Cyklokapron (tranexamic acid) and Amicar (aminocaproic acid).

During the trial, 2,331 high-risk cardiac patients undergoing heart surgery were randomly assigned to one of the three drugs.

"The most important outcome of the trial was a bit of surprise," co-principal investigator Dr. Paul C. Hebert, a critical care physician at Ottawa Hospital, said during Monday's teleconference.

The rate of death from Trasylol was 6 percent versus 3.9 percent and 4 percent for the other two drugs, Hebert said. "This represents a 53 percent of relative risk of dying, which translates into for every 50 patients treated with aprotinin, one patient would die," he said.

Page:  1 | 2 | 3 | Next >>